Dilek KARAMANLIOĞLU, Murat DİZBAY

In vitro combination of tigecycline with other antibiotics in Stenotrophomonas maltophilia isolates

Background/aim: The aim of this study was to determine the usefulness of tigecycline in combination treatment of Stenotrophomonasmaltophilia infections by evaluating the in vitro synergistic effects of tigecycline with various antibiotics using the E-test method.Materials and methods: Synergy testing by E-test was performed with various antibiotic combinations in 10 S. maltophilia isolatesidentified as a cause of infection. The antibiotics used in the study included tigecycline (TGC), cefoperazone-sulbactam (CPS),ceftazidime (TZ), levofloxacin (LEV), and trimethoprim-sulfamethoxazole (cotrimoxazole) (TS). Four different combinations (TGCCPS, TGC-TZ, TGC-LEV, TGC-TS) were studied with the E-test synergy method.Results: S. maltophilia isolates were found to have the highest level of susceptibility to trimethoprim-sulfamethoxazole, tigecycline, andlevofloxacin. The fractional inhibitory concentration (FIC) index was calculated as FIC = MICAB/MICA + MICBA/MICB. The FICindex values were calculated and classified as synergistic (FIC < 0.5), additive (FIC = 0.5–1), indifferent (FIC = 1–4), and antagonistic(FIC > 4). According to FIC index values, synergy was found with the highest rate with TGC-CPS and TGC-LEV combinations (20%).Antagonistic activity was not found in any combination.Conclusion: When trimethoprim-sulfamethoxazole cannot be used because of resistance or allergy, tigecycline alone or in combinationmay be included as an alternative option. Although in vitro results are promising, clinical data are required.

PDF

___

1. Senol E. Stenotrophomonas maltophilia: the significance and role as a nosocomial pathogen. J Hosp Infect 2004; 57: 1-7.
2. Chang YT, Lin CY, Chen YH, Hsueh PR. Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options. Front Microbiol 2015; 6: 893.
3. Falagas ME, Kastoris AC, Vouloumanou EK, Rafailidis PI, Kapaskelis AM, Dimopoulos G. Attributable mortality of Stenotrophomonas maltophilia infections: a systematic review of the literature. Future Microbiol 2009; 4: 1103-1109.
4. Alonso A, Martinez JL. Multiple antibiotic resistance in Stenotrophomonas maltophilia. Antimicrob Agents Chemother 1997; 41: 1140-1142.
5. Zhang L, Li XZ, Poole K. Multiple antibiotic resistance in Stenotrophomonas maltophilia: involvement of a multidrug efflux system. Antimicrob Agents Chemother 2000; 44: 287- 293.
6. Looney WJ, Narita M, Muhlemann K. Stenotrophomonas maltophilia: an emerging opportunist human pathogen. Lancet Infect Dis 2009; 9: 312-323.
7. Mendoza DL, Michael D, Waterer GW, Wunderink RG. Update on Stenotrophomonas maltophilia infection in the ICU. Clin Pulm Med 2007; 14: 17-22.
8. Toleman MA, Bennett PM, Bennett DM, Jones RN, Walsh TR. Global emergence of trimethoprim/sulfamethoxazole resistance in Stenotrophomonas maltophilia mediated by acquisition of sul genes. Emerg Infect Dis 2007; 13: 559-565.
9. Bonfiglio G, Cascone C, Azzarelli C, Cafiso V, Marchetti F, Stefani S. Levofloxacin in vitro activity and time-kill evaluation of Stenotrophomonas maltophilia clinical isolates. J Antimicrob Chemother 2000; 45: 115-117.
10. Galles AC, Jones RN, Sader HS. Antimicrobial susceptibility profile of contemporary clinical strains of Stenotrophomonas maltophilia isolates: can moxifloxacin activity be predicted by levofloxacin MIC results? J Chemother 2008; 20: 38-42.
11. Falagas ME, Valkimadi PE, Huang YT, Matthaiou DK, Hsueh PR. Therapeutic options for Stenotrophomonas maltophilia infections beyond co-trimoxazole: a systematic review. J Antimicrob Chemother 2008; 62: 889-894.
12. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R et al. Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a doubleblind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009; 63: 52-61.
13. Farrell DJ, Sader HS, Jones RN. Antimicrobial susceptibilities of a worldwide collection of Stenotrophomonas maltophilia isolates tested against tigecycline and agents commonly used for S. maltophilia infections. Antimicrob Agents Chemother 2010; 54: 2735-2737.
14. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; TwentySecond Informational Supplement. CLSI Document M100-S23. Wayne, PA, USA: Clinical and Laboratory Standards Institute; 2012.
15. Wyeth Pharmaceuticals. Tygacil (Tigecycline) for Injection [Package Insert]. Philadelphia, PA, USA: Wyeth Pharmaceuticals Inc.; 2005.
16. Chung HS, Hong SG, Kim YR, Shin KS, Whang DH, Ahn JY, Park YJ, Uh Y, Chang CL, Shin JH et al. Antimicrobial susceptibility of Stenotrophomonas maltophilia isolates from Korea, and the activity of antimicrobial combinations against the isolates. J Korean Med Sci 2013; 28: 62-66.
17. Zelenitsky SA, Iacovides H, Ariano RE, Harding GK. Antibiotic combinations significantly more active than monotherapy in an in vitro infection model of Stenotrophomonas maltophilia. Diagn Microbiol Infect Dis 2005; 51: 39-43.
18. Sader HS, Jones RN, Dowzicky MJ, Fritsche TR. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit. Diagn Microbiol Infect Dis 2005; 52: 202-208.
19. Insa R, Cercenado E, Goyanes MJ, Morente A. Bouza E. In vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii and Stenotrophomonas maltophilia. J Antimicrob Chemother 2007; 59: 583-585.
20. Church D, Lloyd T, Peirano G, Pitout J. Antimicrobial susceptibility and combination testing of invasive Stenotrophomonas maltophilia isolates. Scand J Infect Dis 2013; 45: 265-270.
21. Wei C, Ni W, Cai X, Zhao J, Cui J. Evaluation of trimethoprim/ sulfamethoxazole (SXT), minocycline, tigecycline, moxifloxacin, and ceftazidime alone and in combinations for SXT-susceptible and SXT-resistant Stenotrophomonas maltophilia by in vitro time-kill experiments. PLoS One 2016; 11: e0152132.
22. Nicodemo AC, Paez JI. Antimicrobial therapy for Stenotrophomonas maltophilia infections. Eur J Clin Microbiol Infect 2007; 26: 229-237.
23. Tekce YT, Erbay A, Cabadak H, Sen S. Tigecycline as a therapeutic option in Stenotrophomonas maltophilia infections. J Chemother 2012; 24: 150-154.
24. Belvisi V, Fabietti P, del Borgo C, Marocco R, di Vincenzo E, Soscia F, Mastroianni CM. Successful treatment of Stenotrophomonas maltophilia soft tissue infection with tigecycline: a case report. J Chemother 2009; 21: 367-368.
25. Blanquer D, de Otero J, Padilla E, Gomez F, Mayol A, Irigaray R, Espejo P, Rada MA, Makrantoni G, Perez AR. Tigecycline for treatment of nosocomial acquired pneumonia possibly caused by multi-drug resistant strains of Stenotrophomonas maltophilia. J Chemother 2008; 20: 761-763.
26. Wu Y, Shao Z. High-dosage tigecycline for Stenotrophomonas maltophilia bacteremia. Chin Med J 2014; 127: 3199.